

EXPANDING GLOBAL ACCESS TO CHRONIC HEPATITIS C TREATMENTS

It's Gilead's goal to give more people in more places access to treatments for chronic hepatitis C.


A Profound Public Health Issue

THE WORLD HEALTH ORGANIZATION (WHO) ESTIMATES THAT OVER **170 MILLION PEOPLE** are infected worldwide.



Stopping the Virus in Its Tracks

Scientific advances have led to the availability of direct acting antiviral treatment regimens that can cure* most people with hepatitis C.



The WHO has now set a global target of treating

80%

OF ELIGIBLE PEOPLE WITH CHRONIC HEPATITIS C BY

2030

*Cure, also known as sustained virologic response (SVR), is defined as no detectable hepatitis C virus in the blood at 12 or more weeks after therapy is complete.


Access to Treatment Worldwide

Gilead employs a multi-pronged approach to make treatment more affordable to more of the world:



Enabling Generic Production

Gilead has licensed **generic MANUFACTURERS** to provide our medicines to **101** RESOURCE-CONSTRAINED COUNTRIES.



These countries are home to more than

100 million

PEOPLE WITH CHRONIC HEPATITIS C VIRUS.



Strengthening Local Health Systems

Gilead supports numerous in-country research, medical education and training programs to further knowledge and expertise of treating hepatitis C in resource-limited settings.



Driving Research to Find New Cures



GILEAD CONTINUES TO RESEARCH
new treatment options
TO BENEFIT PATIENTS WORLDWIDE.

To learn more about our worldwide approach to increasing treatment access, visit Gilead.com

Follow us on Twitter: @GileadSciences



© 2015 Gilead Sciences, Inc. All rights reserved